What are ADC's

Our services

ADC Review
is made possible by:

NCT01902329 (Clinical Trial/ Vadastuximab Talirine)

Study Title

A Safety Study of SGN-CD33A in AML Patients (NCT01902329)

Trial Description

This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML).

The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be assessed.

This trial is sponsored by Seattle Genetics, Inc.

Study Data

  • Condition:
    • Acute Myelogenous Leukemia
    • Acute Myeloid Leukemia
    • Acute Promyelocytic Leukemia
  • Interventions:
    • Drugs used in this trial
      • HMA
      • SGN-CD33A
  • Phase: I
  • Estimated Enrollment: 225
  • Start: July 2013
  • Estimated Completion: December 2017
  • Last verified: January 2016
  • Last updated: January 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: February 22, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar